GleanMark

ON POINT Trademark

ON POINT is a USPTO trademark filed by Avidity Biosciences, Inc.. Status: Pending.

Trademark Facts

MarkON POINT
Serial Number99175610
StatusPending
Filing Date2025-05-08
Mark TypeWord
Nice Classes005 (Pharmaceuticals), 040 (Material Treatment), 042 (Software & IT), 044 (Medical Services)
OwnerAvidity Biosciences, Inc.
Attorney of RecordAaron D. Hendelman
Prosecution Events24
Latest EventGNS3 on 2026-04-21

Goods & Services

Class 005: Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; none of the foregoing related to pharmacy services or pharmaceutical compounding services; Class 040: Custom manufacturing of oligonucleotide-conjugate based pharmaceutical therapies, oligonucleotide-antibody conjugate based pharmaceutical therapies, and oligonucleotide-antibody fragment conjugate based pharmaceutical therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; none of the foregoing related to pharmacy services or pharmaceutical compounding services; Class 042: Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology; providing medical and scientific research information in the fields of pharmaceuticals, therapeutics, medicines and vaccines; none of the foregoing related to pharmacy services or pharmaceutical compounding services; Class 044: Providing information relating to the diagnostic, prophylactic and therapeutic properties in the field of pharmaceuticals, therapeutics, medicines, and vaccines; online medical information services, namely, providing a website related to the diagnostic, prophylactic and therapeutic properties of medicines and vaccines; none of the foregoing related to medical care centers, medical services, medical clinics, pharmacy services, pharmaceutical compounding services, administration of pharmaceutical preparations, or drop-in medical clinics

Recent Prosecution Activity

DateDocumentType
2026-03-27Response to Office ActionROA
2025-12-04Application Extension to ResponseELR
2025-10-17Non-Final ActionNFIN
2025-10-17Public NotePNR
2025-10-16XSearch Search SummaryXSS
2025-10-16XSearch Search SummaryXSS

USPTO Refusals on Record

Related